Nwam LLC Sells 417 Shares of Zoetis Inc. (NYSE:ZTS)

Nwam LLC reduced its stake in Zoetis Inc. (NYSE:ZTS) by 8.5% during the 4th quarter, Holdings Channel reports. The fund owned 4,491 shares of the company’s stock after selling 417 shares during the period. Nwam LLC’s holdings in Zoetis were worth $732,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. AMF Tjanstepension AB boosted its position in shares of Zoetis by 23.4% during the 3rd quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock worth $20,594,000 after acquiring an additional 20,001 shares in the last quarter. Howard Capital Management Group LLC boosted its position in shares of Zoetis by 0.8% during the 3rd quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock worth $20,489,000 after acquiring an additional 883 shares in the last quarter. Strategic Blueprint LLC boosted its position in shares of Zoetis by 2.4% during the 3rd quarter. Strategic Blueprint LLC now owns 3,016 shares of the company’s stock worth $589,000 after acquiring an additional 72 shares in the last quarter. JFS Wealth Advisors LLC lifted its stake in Zoetis by 217.2% in the 3rd quarter. JFS Wealth Advisors LLC now owns 1,345 shares of the company’s stock valued at $263,000 after purchasing an additional 921 shares during the last quarter. Finally, Cornerstone Wealth Group LLC lifted its stake in Zoetis by 4.9% in the 3rd quarter. Cornerstone Wealth Group LLC now owns 2,019 shares of the company’s stock valued at $394,000 after purchasing an additional 95 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by insiders.

Analyst Ratings Changes

ZTS has been the subject of several research reports. Leerink Partners initiated coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective for the company. UBS Group initiated coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Barclays increased their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Piper Sandler increased their price objective on shares of Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Thursday. Finally, StockNews.com downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $215.90.

Zoetis Price Performance

ZTS stock opened at $167.58 on Friday. The company has a fifty day moving average price of $166.30 and a 200-day moving average price of $177.38. The company has a market capitalization of $75.04 billion, a P/E ratio of 30.64, a PEG ratio of 2.78 and a beta of 0.90. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. As a group, equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.19%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is presently 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.